title: Targeting apoptotic pathways to treat lymphoid malignancies.
abstract: Oncogenic transformation through activation of proliferation generates cellular stress which promotes apoptosis, thereby diminishing the growth advantage of cancerous cells over normal cells. Consequently, many haematological malignancies also harbour aberrations that circumvent apoptosis, with aberrations of TP53 and the BCL2 family being the most common. This educational lecture focuses on current understanding of the role of the intrinsic pathway to apoptosis in lymphoid cancers, its regulation by BCL2 and related proteins, and emerging data on the therapeutic potential of inhibiting BCL2 to induce apoptosis in BCL2-expressing B cell cancers.
authors: Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital.
authors: Andrew W
authors: AW
authors: Roberts
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; C000595707:BCL2 protein, human; D019086:Bridged Bicyclo Compounds, Heterocyclic; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; C579720:venetoclax